Ogilvie Fleet is supplying a variety of cars and vans to the Forth Crossing Bridge Constructors (FCBC) consortium, after winning a competitive tender to supply all vehicles on full maintenance contract hire leases.
Construction on the £790 million Forth Replacement Crossing - the biggest single infrastructure project in Scotland for a generation - began last autumn and is due to open in 2016.
To-date the majority of the vehicles supplied are Renaults and include models from the manufacturer’s Clio, Megane, Laguna, Grand Scenic and Kangoo ranges. In addition, Ogilvie Fleet has delivered Toyota Hilux, Nissan Pathfinder and Nissan X-Trail models.
Contract flexibility was key in Ogilvie Fleet winning the deal and that requirement is being met via the company’s pricing matrix.
Ogilvie Fleet sales and marketing director Nick Hardy said: “Ogilvie prides itself on being able to compile competitive and transparent bespoke solutions for clients according to individual requirements, which is what we have done to win this important contract.”
Carlo Germani, FCBC project director, said: “Ogilvie Fleet offered us the flexibility we were looking for in a competitive, tailor-made package which reflects their reputation for outstanding client service. FCBC is committed to using locally based companies wherever we can and we are very pleased to be working with the team from Ogilvie.”
Also crucial in Ogilvie Fleet winning the contract was access to its recently launched online fleet manager and driver portal MiFleet Showroom.
Hardy added: “The bridge is an historic development for Scotland and as a Scottish-headquartered company Ogilvie Fleet is delighted to be playing its part in the project. We used our expertise to design the fleet policy from scratch based around stringent requirements to ensure budget, work and employee requirements were met.”
Ogilvie Fleet currently has 10,500 vehicles on its books and is aiming to expand its fleet to around 12,000 vehicles through organic growth over the next two to four years.
Login to comment
Comments
No comments have been made yet.